FATE — FATE THERAPEUTICS INC
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on FATE
| date | signal | measured base rate |
|---|---|---|
| 2026-07-13 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-05-04 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-04 | Valamehr Bahram President and CEO | Open-market sale | 43.9K | 2.46 | 108.1K |
| 2026-08-04 | TAHL CINDY See Remarks | Open-market sale | 38.8K | 2.46 | 95.4K |
| 2026-05-20 | Valamehr Bahram President and CEO | Open-market sale | 28.9K | 1.88 | 54.5K |
| 2026-05-20 | TAHL CINDY See Remarks | Open-market sale | 25.6K | 1.88 | 48.1K |
| 2026-05-06 | TAHL CINDY See Remarks | Option exercise | 122.2K | 1.32 | 161.3K |
| 2026-05-06 | TAHL CINDY See Remarks | Option exercise | 44.4K | 1.05 | 46.7K |
| 2026-05-05 | EPSTEIN ROBERT S Director | Option exercise | 25.0K | 1.69 | 42.2K |
| 2026-05-05 | RASTETTER WILLIAM H Director | Option exercise | 25.0K | 1.69 | 42.2K |
| 2026-04-20 | Redmile Group, LLC Director | Other Acquisition/Disposition | 9.0M | 0.00 | 0 |
| 2026-04-20 | Redmile Group, LLC Director | Other Acquisition/Disposition | 9.0M | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Redmile Group, LLC | 15.4M | 12.9M |
| BlackRock, Inc. | 12.1M | 10.1M |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.0M | 4.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.0M | 4.1M |
| TWO SIGMA INVESTMENTS, LP | 4.2M | 3.5M |
| JOHNSON & JOHNSON | 4.1M | 3.4M |
| AQR CAPITAL MANAGEMENT LLC | 3.6M | 3.0M |
| RENAISSANCE TECHNOLOGIES LLC | 3.6M | 3.0M |
| GEODE CAPITAL MANAGEMENT, LLC | 3.1M | 2.6M |
| STATE STREET CORP | 2.7M | 2.3M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Fate Therapeutics Inc (FATE) filed form 8-K · 2026-08-13 · SEC EDGAR
Ask the AI about FATE
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →